Treatment of Ethylene Glycol Poisoning with Documented Plasma Concentration >20 mg/dL or Osmol Gap Elevation

This protocol addresses ethylene glycol poisoning confirmed by direct laboratory measurement or by a combination of metabolic and clinical criteria. It covers the antidote-centred approach indicated when specific diagnostic thresholds are met.

Clinical Scenario

This protocol applies when any one of the following is present:

The patient must have no hypersensitivity to fomepizole. Fomepizole is the preferred antidote over ethanol — particularly when there is altered consciousness, co-ingestion of CNS depressants, active hepatic disease, or a critically ill presentation with unexplained anion-gap metabolic acidosis.

Treatment Overview

Management centres on prompt intravenous antidote therapy, alongside concurrent supportive measures that address metabolic correction and symptomatic management in selected patients.

The complete regimen — drug, dosing sequence, continuation criteria, and full supportive care algorithm — is available in the full structured protocol.

Clinical Goals

Serum ethylene glycol undetectable or <20 mg/dL, patient asymptomatic, and normal arterial pH.

Instant Access to Structured Evidence-Based Regimens
References

DOI: 10.1081/clt-100102445

View source ↗